Management of small cell carcinoma of the lung: therapy, staging, and biochemical markers.
A chemotherapeutic regimen consisting of BCNU, cyclophosphamide, vincristine, and procarbazine was evaluated in 43 patients with small cell carcinoma of the lung. The majority of patients received radiation therapy of the primary tumor, but chemotherapy alone was utilized in a group of patients with widely disseminated disease. In addition to thorough staging with radioisotope scans and bone marrow biopsies, a study of calcitonin and histaminase as biochemical markers was performed. The BCVP chemotherapy resulted in a complete and partial response rate of 53% when given alone or in conjunction with radiotherapy. The survival data are preliminary, but the complete responders do have a statistically significant better survival (mean of + -95 days) than the partial responders and nonresponders. Hypercalcitonemia was not detected in our patients, but elevated histaminase activity was found in eight of 24 patients with small cell carcinoma and in only one of 19 patients with squamous and large cell carcinoma.
D000328:Adult; D000368:Aged; D006631:Amine Oxidase (Copper-Containing) / Q000032:analysis; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000201:enzymology / Q000532:radiotherapy; D002330:Carmustine / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011344:Procarbazine / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use*
D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D006631:Amine Oxidase (Copper-Containing); D002330:Carmustine